Suraj S Vasanthi
Overview
Explore the profile of Suraj S Vasanthi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Massey N, Vasanthi S, Gimenez-Lirola L, Tyler H, Thippeswamy T
Sci Rep
. 2025 Mar;
15(1):9021.
PMID: 40089647
Organophosphate (OP) nerve agents, such as soman (GD), pose great risk to neurological health by inhibiting acetylcholinesterase, leading to seizures, epilepsy, and behavioral deficits. While acute treatment may alleviate immediate...
2.
Meyer C, Grego E, Vasanthi S, Rao N, Massey N, Holtkamp C, et al.
Antioxidants (Basel)
. 2023 Dec;
12(12).
PMID: 38136181
NADPH oxidase (NOX) is a primary mediator of superoxides, which promote oxidative stress, neurodegeneration, and neuroinflammation after diisopropylfluorophosphate (DFP) intoxication. Although orally administered mitoapocynin (MPO, 10 mg/kg), a mitochondrial-targeted NOX...
3.
Putra M, Vasanthi S, Rao N, Meyer C, Van Otterloo M, Thangi L, et al.
J Pharmacol Exp Ther
. 2023 Dec;
388(2):724-738.
PMID: 38129129
Organophosphate (OP) nerve agent (OPNA) intoxication leads to long-term brain dysfunctions. The ineffectiveness of current treatments for OPNA intoxication prompts a quest for the investigation of the mechanism and an...
4.
Vasanthi S, Massey N, Nair S, Mochel J, Showman L, Thippeswamy T
Front Vet Sci
. 2023 Nov;
10:1297221.
PMID: 38026620
Saracatinib/AZD0530 (SAR), a Src tyrosine kinase inhibitor, mitigates seizure-induced brain pathology in epilepsy models upon repeated oral dosing. However, repeated dosing is stressful and can be challenging in some seizing...
5.
Vasanthi S, Rao N, Samidurai M, Massey N, Meyer C, Gage M, et al.
J Neuroinflammation
. 2023 Jul;
20(1):163.
PMID: 37438764
Background: Acute exposure to seizurogenic organophosphate (OP) nerve agents (OPNA) such as diisopropylfluorophosphate (DFP) or soman (GD), at high concentrations, induce immediate status epilepticus (SE), reactive gliosis, neurodegeneration, and epileptogenesis...
6.
Meyer C, Rao N, Vasanthi S, Pereira B, Gage M, Putra M, et al.
Front Cell Neurosci
. 2023 Jul;
17:1195843.
PMID: 37416507
Organophosphates (OP) are highly toxic chemical nerve agents that have been used in chemical warfare. Currently, there are no effective medical countermeasures (MCMs) that mitigate the chronic effects of OP...
7.
Vasanthi S, Rao N, Samidurai M, Massey N, Meyer C, Gage M, et al.
Res Sq
. 2023 May;
PMID: 37214912
Acute exposure to seizurogenic organophosphate (OP) nerve agents (OPNA) such as diisopropylfluorophosphate (DFP) or soman (GD), at high concentrations, induce immediate (SE), reactive gliosis, neurodegeneration, and epileptogenesis as a consequence....
8.
Gage M, Vasanthi S, Meyer C, Rao N, Thedens D, Kannurpatti S, et al.
Epilepsia Open
. 2023 Jan;
8(2):399-410.
PMID: 36718979
Objective: Exposure to the nerve agent, soman (GD), induces status epilepticus (SE), epileptogenesis, and even death. Although rodent models studying the pathophysiological mechanisms show females to be more reactive to...
9.
Rao N, Meyer C, Vasanthi S, Massey N, Samidurai M, Gage M, et al.
Front Cell Dev Biol
. 2022 May;
10:895092.
PMID: 35620057
Sex is a biological variable in experimental models. In our previous diisopropylfluorophosphate (DFP) studies, female rats required a higher dose of DFP to achieve a somewhat similar severity of status...
10.
Gage M, Rao N, Samidurai M, Putra M, Vasanthi S, Meyer C, et al.
Front Cell Neurosci
. 2022 Feb;
15:798247.
PMID: 35197823
Modeling a real-world scenario of organophosphate nerve agent (OPNA) exposure is challenging. Military personnel are premedicated with pyridostigmine, which led to the development of OPNA models with pyridostigmine/oxime pretreatment to...